DFCon 2022

Thursday, September 29, 2022, 7:00 AM - Saturday, October 1, 2022, 4:30 PM, Hilton Los Angeles/Universal City

AMA PRA Category 1 Credits™ (17.50 hours), Non-Physician Attendance (17.50 hours)

On September 29th-October 1st, 2022, the 22nd edition of the interdisciplinary Diabetic Foot Conference (DFCon) will be held in Los Angeles at the Hilton Universal Conference Hotel. It will also be possible to attend virtually – as the program will also be livestreamed.

Each year, DFCon gathers influential speakers and delivers outstanding scientific content. DFCon will not only do that, it will also present new opportunities for networking and many participants and speakers who did not yet have the opportunity to experience DFCon previously due to travel and resource restrictions will get the chance now with DFCon. As always, the DFCon conference allows the best in their field to come together and learn from each other. DFCon also serves as a hands-on, dynamic congress where delegates can use the experience to immediately bring impact to their daily clinical practice. You will learn more about the different topics and sessions on the following pages.

There is a challenge facing us: redefining the role of a medical congress in the 21st century. The physician from twenty years ago is different from the physician of today. Knowledge is now available at their fingertips. The information is no longer an end in itself, it’s a conversation starter. DFCon exists to facilitate this meeting of physicians where ideas can be exchanged freely. DFCon is widely acknowledged as being a leader in discovery. Next-generation endovascular therapies, wearable robots, spray-on skin, sociomicrobiology, smart textiles, phage therapy, augmented reality and injectable sensors have all made their debut at DFCon.

1. Identify updated information to provide patient care in the discipline of limb preservation.
2. Explain new techniques in collaborating and communicating with teams to ensure best practices in patient care, education and research in limb preservation.
3. Apply quality improvement in areas of limb preservation. Utilize updated information as outlined in program as related to limb preservation diagnosis and diseases.
4. Outline new techniques and studies along with innovative approaches related to patient care, medical knowledge, practice-based learning and improvement, and system-based practices.

The Keck School of Medicine of the University of Southern California designates this Live Activity activity for a maximum of 17.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Cancellation Policy

Cancellations must be received by the USC Office of CME by email only by September 19, 2022, 12:00 pm PDT for a refund. A $50 cancellation fee will be applied. In the event of course cancellation by conference organizers, all registration fees will be fully refunded. USC will not refund any travel costs incurred.


Accessibility Statement
 
Keck School of Medicine Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the USC Office of CME at [email protected].

The Keck School of Medicine Healthcare System School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Keck School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.